Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 vs investigator's choice chemotherapy in HER2-negative, EGFR-positive recurrent/metastatic breast cancer
CTR20260662Phase 3Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CPO301 in breast cancer, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Feb 2026; status: active.
02
Drugs
CPO301
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20260662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260662.